RU2012128509A - Способы лечения заболеваний желудочно-кишечного тракта - Google Patents

Способы лечения заболеваний желудочно-кишечного тракта Download PDF

Info

Publication number
RU2012128509A
RU2012128509A RU2012128509/04A RU2012128509A RU2012128509A RU 2012128509 A RU2012128509 A RU 2012128509A RU 2012128509/04 A RU2012128509/04 A RU 2012128509/04A RU 2012128509 A RU2012128509 A RU 2012128509A RU 2012128509 A RU2012128509 A RU 2012128509A
Authority
RU
Russia
Prior art keywords
cys
asp
glu
tyr
seq
Prior art date
Application number
RU2012128509/04A
Other languages
English (en)
Russian (ru)
Inventor
Марк Дж. Карри
Дэниел П. Зиммер
Ангелика Фретцен
Марко Кесслер
Брайан М. КАЛИ
Original Assignee
Айронвуд Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айронвуд Фармасьютикалз, Инк. filed Critical Айронвуд Фармасьютикалз, Инк.
Publication of RU2012128509A publication Critical patent/RU2012128509A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2012128509/04A 2009-12-07 2010-12-07 Способы лечения заболеваний желудочно-кишечного тракта RU2012128509A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26731609P 2009-12-07 2009-12-07
US61/267,316 2009-12-07
PCT/US2010/059294 WO2011071927A2 (en) 2009-12-07 2010-12-07 Treatments for gastrointestinal disorders

Publications (1)

Publication Number Publication Date
RU2012128509A true RU2012128509A (ru) 2014-01-20

Family

ID=43530704

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012128509/04A RU2012128509A (ru) 2009-12-07 2010-12-07 Способы лечения заболеваний желудочно-кишечного тракта

Country Status (7)

Country Link
US (3) US8735360B2 (enExample)
EP (1) EP2509992B1 (enExample)
JP (2) JP5984675B2 (enExample)
KR (1) KR20120103689A (enExample)
CN (1) CN102822194B (enExample)
RU (1) RU2012128509A (enExample)
WO (1) WO2011071927A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR20120103689A (ko) 2009-12-07 2012-09-19 아이언우드 파마슈티컬스, 인코포레이티드 위장 장애의 치료
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170804A1 (en) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9527887B2 (en) * 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
CN104053449B (zh) * 2011-08-17 2016-12-07 硬木药品公司 胃肠疾患的治疗
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
KR101714448B1 (ko) * 2015-07-10 2017-03-09 가톨릭대학교 산학협력단 위 점막 손상의 예방 및 치료용 조성물 및 헬리코박터 파이로리 균의 우레아제 활성 저해능을 지닌 조성물
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011694A1 (en) 1993-10-26 1995-05-04 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5962220A (en) 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
WO1999039748A1 (en) * 1998-02-06 1999-08-12 Nycomed Imaging As Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
AU2001256315A1 (en) 2000-04-22 2001-11-07 Ipf Pharmaceuticals Gmbh Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes type 2
GB0105224D0 (en) 2001-03-02 2001-04-18 Nycomed Amersham Plc Improved peptide-chelate conjugates
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BR122018074353B8 (pt) * 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2612309C (en) * 2005-06-16 2014-12-16 Mohammed Saeed Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent
EP1940441A4 (en) 2005-08-19 2010-01-27 Ironwood Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
EP2650303A1 (en) * 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
RS60101B1 (sr) 2008-08-15 2020-05-29 Ironwood Pharmaceuticals Inc Formulacije koje sadrže linaklotid za oralnu primenu
WO2010027405A2 (en) 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration
MX350046B (es) * 2009-11-09 2017-08-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
KR20120103689A (ko) 2009-12-07 2012-09-19 아이언우드 파마슈티컬스, 인코포레이티드 위장 장애의 치료
EP2605786A4 (en) 2010-06-09 2014-03-12 Combimab Inc THERAPEUTIC PEPTIDES

Also Published As

Publication number Publication date
WO2011071927A3 (en) 2011-10-13
WO2011071927A2 (en) 2011-06-16
US8735360B2 (en) 2014-05-27
JP2013512960A (ja) 2013-04-18
US20130130995A1 (en) 2013-05-23
EP2509992A2 (en) 2012-10-17
US20140256634A1 (en) 2014-09-11
JP2016117764A (ja) 2016-06-30
KR20120103689A (ko) 2012-09-19
US20150119328A1 (en) 2015-04-30
JP5984675B2 (ja) 2016-09-06
CN102822194B (zh) 2016-10-26
CN102822194A (zh) 2012-12-12
EP2509992B1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
JP2013512960A5 (enExample)
JP2013510182A5 (enExample)
FI92326C (fi) LHRH:n nonapeptidi- ja dekapeptidianalogeja, jotka ovat käyttökelpoisia LHRH:n antagonisteina
RU2011138011A (ru) Миметики аполипопротеина а-i
US20140038881A1 (en) Therapeutic Peptides
CA2779482A1 (en) Treatments for gastrointestinal disorders
US8735360B2 (en) Treatments for gastrointestinal disorders
WO2001007475A1 (en) Novel peptides
RU2011110504A (ru) Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды
RU2012105355A (ru) Производное аналога glp-1 или его фармацевтически приемлемые соли и их применение
JP2009108078A5 (enExample)
RU2012109415A (ru) Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы
JP2020037570A (ja) オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
HK1213785A1 (zh) 血管紧张素的口服制剂
CA2984437A1 (en) Compositions for colon cleansing and the treatment of gastrointestinal disorders
CA2912635A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
CA2835624A1 (en) Treatments for gastrointestinal disorders
JP5982473B2 (ja) 血清リンを調節するための治療剤
WO2022052471A1 (zh) 双特异性融合多肽化合物
WO2012170766A1 (en) Treatments for gastrointestinal disorders
JP2005060315A (ja) 製剤組成物
EP3452072A2 (en) Novel peptides and peptidomimetics
JP2005126360A (ja) 新規なポリペプチドで構成されたコラゲナーゼ阻害剤
TH145794A (th) สารบำบัดสำหรับความผิดปกติของโรคกระเพาะอาหารและลำไส้ (Gastrointestinal Disorders)
RU2008129731A (ru) Новые пептиды-т-хелперные антигенные детерминанты (thd)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150310